Genentech, a prominent subsidiary of Roche, is undergoing significant layoffs and restructuring efforts, which are slated to impact various roles at its South San Francisco operations. This development follows a recent announcement that 93 employees will be laid off starting in early October. The
U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.
Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such
MSD, also known as Merck in North America, has taken a significant step to enhance its therapeutic portfolio by investing $1.3 billion in the acquisition of CN201 from Curon Biopharmaceutical. The investigational bispecific antibody is poised to change the landscape of treatments for B-cell
The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now
The journey from a new chemical entity (NCE) to a marketable drug product is a complex, multifaceted process that demands an intricate blend of scientific expertise and practical knowledge. The transformation involves a deep understanding of organic chemistry, analytical development, pharmaceutical
